PMC6489367_01
Colour fundus photographs (taken by TRC-50DX, Topcon, Tokyo, Japan) and horizontal OCT images (acquired by Heidelberg Spectralis, Heidelberg Engineering, Heidelberg, Germany) before and after the cessation of axitinib treatment. a, b Fundus images in July 2015. Multiple large soft exudates were seen in the right eye while no abnormality was observed in the left eye. c, d OCT showed a hyperreflective inner layer in the right eye and a normal appearance in the left eye. Retinal thickness at the temporal macula appeared thinner in the right eye than in the left eye. e The soft exudates decreased in size and number within 2 weeks after stopping axitinib intake. g The hyperreflective inner layer became inconspicuous on OCT. f, h The right eye returned to normal appearance 2 months after the end of axitinib treatment.
cop-0010-0005-g01.jpg
PMC6489367_01_cop-0010-0005-g01.jpg
F1
His best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/12 in the left eye. His right fundus showed multiple soft exudates while his left fundus exhibited normal appearance (Fig. 1a, b). The soft exudates then gradually subsided by 2 months (Fig. 1c, d) although his right BCVA dropped to 20/63.
Fluorescein angiogram/indocyanine green angiogram (FA/IA) of the right eye in July 2015. a The choroidal flush and the following arterial fluorescence became visible 28 s after injection on FA. b Within the next 10 s, fluorescein perfusion was observed only in the superotemporal branch of the central retinal artery on FA. Choroidal filling was normal on IA. c The laminar pattern of retinal venous flow was still detectable on FA 70 s after injection. d There was no evident abnormal finding except for fluorescein blocking corresponding to soft exudates on the late phase. FA/IA was performed with HRA (Heidelberg Engineering).
cop-0010-0005-g02.jpg
PMC6489367_01_cop-0010-0005-g02.jpg
F2
Fluorescein angiography disclosed a significant filling delay of fluorescein dye in the right eye, and indocyanine green angiography revealed no remarkable abnormalities except for blocked hypofluorescence (Fig. 2).